Form 4: Nurix Therapeutics Chief Legal Officer Exercises Options and Sells Shares

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Christine Ring, the Chief Legal Officer of Nurix Therapeutics, executed a transaction involving the company's stock on December 2, 2024.
• She exercised 5,760 stock options at a price of $1.86 per share.
• Following the exercise, she sold 5,760 shares at a weighted average price of $21.7283 per share.
• The sale price ranged from a low of $21.48 to a high of $22.09 per share.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan.
• After these transactions, Ms. Ring directly owns 28,084 shares of common stock and 59,746 employee stock options.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing detailing an insider transaction. It doesn't indicate any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Amgen, Gilead, and Regeneron.
• The vesting schedule of the options, with a 1/4 vesting initially and then monthly vesting, is a typical structure for employee stock options.
• The price range of the stock sale is within the normal fluctuations of the market, and the weighted average price is a standard metric for reporting such transactions.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it represents a small portion of the total outstanding shares.
• The sale of shares by an executive could be perceived as a negative signal by some investors, but the pre-planned nature of the transaction mitigates this concern.

Key Dates

Keywords

insider trading, stock options, Rule 10b5-1, securities, NRIX, Nurix Therapeutics, stock sale, executive compensation